middle.news
Bioxyne Boosts FY2025 Revenue Forecast to $28M on Psychedelic Medicine Surge
8:41am on Thursday 12th of June, 2025 AEST
•
Pharmaceuticals
Read Story
Bioxyne Boosts FY2025 Revenue Forecast to $28M on Psychedelic Medicine Surge
8:41am on Thursday 12th of June, 2025 AEST
Key Points
FY2025 revenue guidance upgraded from $25M to $28M
H1 FY2025 revenue surged 267% over previous half
H2 FY2025 expected to grow 226% year-on-year
Commercial batch production of MDMA capsules to start in July
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Bioxyne (ASX:BXN)
OPEN ARTICLE